Normal view

Received — 2 April 2026 ⏭ Nature Medicine

Nature Medicine
A deep joint-learning proteomics model for diagnosis of six conditions associated with dementia Lijun An · Alexa Pichet Binette · Ines Hristovska · Gabriele Vilkaite · Yu Xiao · Romina Zendehdel · Zijian Dong · Bart Smets · Rowan Saloner · Shinya Tasaki · Ying Xu · Varsha Krish · Farhad Imam · Shorena Janelidze · Danielle van Westen · Erik Stomrud · Christopher D. Whelan · Sebastian Palmqvist · Rik Ossenkoppele · Niklas Mattsson-Carlgren · Oskar Hansson · Jacob W. Vogel
Nature Medicine, Published online: 31 March 2026; doi:10.1038/s41591-026-04303-yProtAIDe-Dx is a deep joint-learning model that uses plasma proteomics to provide simultaneous probabilistic diagnoses across six conditions associated with aging.
31 March 2026 at 08:00

A deep joint-learning proteomics model for diagnosis of six conditions associated with dementia

By: Lijun An · Alexa Pichet Binette · Ines Hristovska · Gabriele Vilkaite · Yu Xiao · Romina Zendehdel · Zijian Dong · Bart Smets · Rowan Saloner · Shinya Tasaki · Ying Xu · Varsha Krish · Farhad Imam · Shorena Janelidze · Danielle van Westen · Erik Stomrud · Christopher D. Whelan · Sebastian Palmqvist · Rik Ossenkoppele · Niklas Mattsson-Carlgren · Oskar Hansson · Jacob W. Vogel

31 March 2026 at 08:00

Nature Medicine, Published online: 31 March 2026; doi:10.1038/s41591-026-04303-y

ProtAIDe-Dx is a deep joint-learning model that uses plasma proteomics to provide simultaneous probabilistic diagnoses across six conditions associated with aging.

Nature Medicine
Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial Princess U. Ogbogu · Florence Roufosse · Praveen Akuthota · Piotr Kuna · Matthieu Groh · Andreas Reiter · Akira Yokota · Salman H. Siddiqui · Pim G. N. J. Mutsaers · Bing Li · Paneez Khoury · Lila M. Bahadori · Artur Bednarczyk · Gerben Bouma · Laura G. Brooks · Jorge Ferreira · Hanna Grindebacke · Calvin N. Ho · Priya Jain · Rebecca L. Palmer · Maria L. Jison · Amy D. Klion
Nature Medicine, Published online: 31 March 2026; doi:10.1038/s41591-026-04315-8Benralizumab (an anti-IL-5 receptor α antibody), compared to placebo, significantly reduced the risk of first flare in patients with hypereosinophilic syndrome.
31 March 2026 at 08:00

Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial

Nature Medicine

By: Princess U. Ogbogu · Florence Roufosse · Praveen Akuthota · Piotr Kuna · Matthieu Groh · Andreas Reiter · Akira Yokota · Salman H. Siddiqui · Pim G. N. J. Mutsaers · Bing Li · Paneez Khoury · Lila M. Bahadori · Artur Bednarczyk · Gerben Bouma · Laura G. Brooks · Jorge Ferreira · Hanna Grindebacke · Calvin N. Ho · Priya Jain · Rebecca L. Palmer · Maria L. Jison · Amy D. Klion

31 March 2026 at 08:00

Nature Medicine, Published online: 31 March 2026; doi:10.1038/s41591-026-04315-8

Benralizumab (an anti-IL-5 receptor α antibody), compared to placebo, significantly reduced the risk of first flare in patients with hypereosinophilic syndrome.